Spring direct naar de hoofdnavigatie of de inhoud
‘In the end it's all about the value that the patent adds to the product.’
Mark Einerhand

Mark Einerhand

  • Life Sciences
  • European and Dutch Patent Attorney
  • Partner

Mark Einerhand has been active in the patent world since 1998, when he made the switch from a biotech startup to V.O.

Mark’s career started in science. After his studies of molecular biology at the University of Amsterdam, he took his PhD in medical science inLeiden, in 1992. He was a visiting scientist at Cornell University in New York and the MRC at Mill Hill in London.

Continue reading

His particular expertise lies in the field of medical (bio)technology, diagnostics and medicines. Because of his background at Introgene/Crucell, Mark has a special affinity with Life Science startups. He has a wide experience in patent cases before the court in The Hague.

Working experience

  • Patent Attorney, V.O. (1998-present)
  • IntroGene (now Crucell), Rijswijk (1995)
  • Post-Doc at Leiden University (1993)
  • Medical Research Council, Mill Hill, London (1992)
  • Visiting Scientist, Cornell University New York (1992)

Education

  • PhD in Medicine, Leiden University (1992)
  • MSc in Biochemistry, University of Amsterdam (1987), Major in Molecular Oncology, Dutch Cancer Institute

Publications

  • Co-author of article ‘The patentability of stem cells in Europe’, IAM Life Sciences 2015.
    Einerhand, M.P.W. (2011): Advance offering of generics found to infringe. Managing Intellectual Property: Vol 205: page: 87.
  • Einerhand M.P.W. (2010): A contribution to: Legal and intellectual property issues associated with stem cells. In: Stem Cells; scientific facts and fiction, (C. Mummery; I. Wilnut, A van de Stolpe and
    B.A.J. Roelen), Academic Press: Elsevier.
  • Einerhand M.P.W. and van Melle, J (2004): Patenting of inventions in the field of bio-informatics.
    In: The new avenues in Bioinformatics, (Seckbach, J and Rubin, E eds), Kluwer Academic Publishers, the Netherlands.
  • Principle inventor on Patents and Patent Applications: Einerhand, M.P.W. and Valerio (1997). WO 98/32870: US 6,232,105: A conditional replication and expression system. Einerhand, M.P.W. and Valerio (1997). WO 99/32647: Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into chromosomal DNA of target cells in gene therapy. Einerhand, M.P.W. and Valerio (1996). WO98/24924: NZ 336185:
  • Transduction of primate hemopoietic repopulating stem cells. Einerhand, M.P.W. and Valerio (1995). WO 97/20943: US 6,140,103: Regulated protein expression in stably transfected mammalian cells. Einerhand, M.P.W. (1992) Gene transfer into hemopoietic stem cells: prospects for human gene therapy. University of Leiden.

Professional & Community Activities

  • Member of the Steering Committee World IP Forum 2015
    Former member of the European Qualifying Examination committee III

Languages

  • English
  • Dutch
  • German

Also see these experts

Marijke Westra

Marijke Westra

  • European and Dutch Patent Attorney
  • Associate
Tamara Elmore

Tamara Elmore

  • European and Dutch Patent Attorney
  • United States Patent Agent
  • Partner
More experts

News

The genetic scissors

Scientists use technologies that can manipulate the genetic information in cells to ascertain the function of these genes, among other things. That is time consuming, difficult and an often impossible job. Now, in 2020, it is possible to change the genome – the code of life – within a few weeks. This is possible using […]Continue reading

Fast-track Netherlands Patent Office (OCN) search procedure for corona control products

  The Netherlands Patent Office (OCN), that falls under the Netherlands Enterprise Agency, is offering an accelerated search procedure in digital patent databases for inventions that play a role in controlling the coronavirus.Continue reading

New partners and senior associates at V.O.

As of 1 January 2021, V.O. has two new partners: Tamara Elmore and Annemiek Tepper.Continue reading